28 July 2022
04 July 2022
26 April 2022
TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies in 2022
IMC SDC-1801 CTA submission, Aug 2022
BioTrinity, April 2022
IMC Half Year Results, Feb 2022
IMC Full Year Results, Oct 2021